142 related articles for article (PubMed ID: 29509603)
1. Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina.
Piñero F; Marciano S; Fernández N; Silva J; Zambelo Y; Cobos M; Zerega A; Ridruejo E; Miguez C; Ameigeiras B; D'Amico C; Gaite L; Coronel M; Bermúdez C; Rosales C; Romero G; McCormack L; Reggiardo V; Colombato L; Gadano A; Rubinstein F; Silva M;
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):376-383. PubMed ID: 29509603
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania.
Guarino M; Tortora R; de Stefano G; Coppola C; Morisco F; Salomone Megna A; Izzo F; Nardone G; Piai G; Adinolfi LE; D'Adamo G; Gaeta GB; Messina V; Francica G; De Girolamo V; Coppola N; Persico M; Di Costanzo GG;
J Gastroenterol Hepatol; 2018 May; 33(5):1123-1130. PubMed ID: 28994145
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
[TBL] [Abstract][Full Text] [Related]
4. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm.
Richani M; Kolly P; Knoepfli M; Herrmann E; Zweifel M; von Tengg-Kobligk H; Candinas D; Dufour JF
Ann Hepatol; 2016; 15(1):82-90. PubMed ID: 26626644
[TBL] [Abstract][Full Text] [Related]
5. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.
Farinati F; Vanin V; Giacomin A; Pozzan C; Cillo U; Vitale A; Di Nolfo AM; Del Poggio P; Benvegnu' L; Rapaccini G; Zoli M; Borzio F; Giannini EG; Caturelli E; Trevisani F;
Liver Int; 2015 Jan; 35(1):223-31. PubMed ID: 25074434
[TBL] [Abstract][Full Text] [Related]
6. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
Vitale A; Morales RR; Zanus G; Farinati F; Burra P; Angeli P; Frigo AC; Del Poggio P; Rapaccini G; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Trevisani F; Cillo U;
Lancet Oncol; 2011 Jul; 12(7):654-62. PubMed ID: 21684210
[TBL] [Abstract][Full Text] [Related]
7. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage.
Kikuchi L; Chagas AL; Alencar RSSM; Tani C; Diniz MA; D'Albuquerque LAC; Carrilho FJ
Clinics (Sao Paulo); 2017 Aug; 72(8):454-460. PubMed ID: 28954003
[TBL] [Abstract][Full Text] [Related]
8. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.
Wallace MC; Huang Y; Preen DB; Garas G; Adams LA; MacQuillan G; Tibballs J; Ferguson J; Samuelson S; Jeffrey GP
Dig Dis Sci; 2017 Aug; 62(8):2182-2192. PubMed ID: 28547649
[TBL] [Abstract][Full Text] [Related]
9. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
[TBL] [Abstract][Full Text] [Related]
10. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable.
Wallace MC; Knuiman M; Huang Y; Garas G; Adams LA; MacQuillan G; Preen DB; Jeffrey GP
Dig Dis Sci; 2018 Sep; 63(9):2277-2284. PubMed ID: 29808245
[TBL] [Abstract][Full Text] [Related]
12. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.
Borzio M; Fornari F; De Sio I; Andriulli A; Terracciano F; Parisi G; Francica G; Salvagnini M; Marignani M; Salmi A; Farinati F; Carella A; Pedicino C; Dionigi E; Fanigliulo L; Cazzaniga M; Ginanni B; Sacco R;
Future Oncol; 2013 Feb; 9(2):283-94. PubMed ID: 23414477
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
14. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations.
Sangiovanni A; Triolo M; Iavarone M; Forzenigo LV; Nicolini A; Rossi G; La Mura V; Colombo M; Lampertico P
Liver Int; 2018 Sep; 38(9):1624-1634. PubMed ID: 29791968
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
16. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
[TBL] [Abstract][Full Text] [Related]
17. Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification.
Furukawa K; Shiba H; Horiuchi T; Shirai Y; Haruki K; Fujiwara Y; Sakamoto T; Gocho T; Yanaga K
J Hepatobiliary Pancreat Sci; 2017 Apr; 24(4):199-205. PubMed ID: 28160422
[TBL] [Abstract][Full Text] [Related]
18. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
[TBL] [Abstract][Full Text] [Related]
19. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective.
Yang T; Lau WY; Zhang H; Huang B; Lu JH; Wu MC
World J Gastroenterol; 2015 Jul; 21(27):8256-61. PubMed ID: 26217077
[TBL] [Abstract][Full Text] [Related]
20. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A.
Jung YK; Jung CH; Seo YS; Kim JH; Kim TH; Yoo YJ; Kang SH; Yim SY; Suh SJ; An H; Yim HJ; Yeon JE; Byun KS; Um SH
J Gastroenterol Hepatol; 2016 Feb; 31(2):467-74. PubMed ID: 26332049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
